Universal Cells' CEO, Dr. Claudia Mitchell has received the 2016 Women in Life Sciences Award at the Life Science Innovation Northwest (LSINW) Conference. The LSINW Women in Life Science award has been established to recognize women who are thought-leaders in their fields and shaping the future of their industries. As more companies continue to put [...]
Universal Cells Inc. and Healios K.K. enter Collaborative Research Agreement with Exclusive Option to Produce Universal Donor iPSCs
Seattle, WA－Universal Cells Inc. (Seattle WA, USA) and HEALIOS K.K. (“Healios”) (Tokyo, Japan) have entered into a collaborative research and exclusive option agreement to create therapeutic off-the-shelf iPSCs. The partnership will focus on the production of Universal Donor iPSCs by editing the genes required for antigen presentation. “Partnering with the world’s leading company in iPSC [...]
Adaptimmune offices in Philadelphia PHILADELPHIA, PA. and OXFORD, UK, December 1, 2015 – Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and Seattle-based Universal Cells Inc., a genome editing company developing universal donor stem cells, today announced that they have entered into a [...]
The Universal Cells team will be attending the 2015 Stem Cell Meeting on the Mesa in San Diego, California. To schedule a meeting time in advance please contact us through the online partnering forum.
Universal Cells has recently been awarded a Phase II SBIR Grant from the US National Institutes of Health (NIGMS). The award provides non-dilutive funding to carry out critical in vivo experiments to enhance proof-of-concept for the clinical use of Universal Donor Stem Cells.
David Russell, our CSO, was recognized as the 2014 Inventor of the Year at the University of Washington. Dr. Russell’s inventions have made a profound impact on the commercialization of genome editing technologies. Learn more about Dr. Russell's research program